CD33 and neoplasm: Early studies using beta-particle emitters such as Iodine-131 and Yttrium-90 conjugated to anti-CD33 antibodies (M195 and huM195) demonstrated some reduction in leukemic burden, but their therapeutic impact was modest, especially in patients with high tumor loads39,40.